Galvus Review Delayed For Safety Analysis Of Primate Skin Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.
You may also be interested in...
Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Merck Builds On Januvia Momentum With Two Supplementary Claims
Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.